These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 28461224)
1. Responsiveness to Ipratropium Bromide in Male and Female Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease. Li X; Obeidat M; Zhou G; Leung JM; Tashkin D; Wise R; Connett J; Joubert P; Bossé Y; van den Berge M; Brandsma CA; Nickle DC; Hao K; Paré PD; Sin DD EBioMedicine; 2017 May; 19():139-145. PubMed ID: 28461224 [TBL] [Abstract][Full Text] [Related]
2. Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease. Levin DC; Little KS; Laughlin KR; Galbraith JM; Gustman PM; Murphy D; Kram JA; Hardie G; Reuter C; Ostransky D; McFarland K; Petty TL; Silvers W; Rennard SI; Mueller M; Repsher LH; Zuwallack RL; Vale R Am J Med; 1996 Jan; 100(1A):40S-48S. PubMed ID: 8610716 [TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies. Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804 [TBL] [Abstract][Full Text] [Related]
4. Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study. Singh D; Zhu CQ; Sharma S; Church A; Kalberg CJ Pulm Pharmacol Ther; 2015 Apr; 31():85-91. PubMed ID: 25197005 [TBL] [Abstract][Full Text] [Related]
5. Bronchodilating effect of combined therapy with ipratropium bromide and ondansetron in patients with COPD. Pauwels R; Joos GF; Fogarty C; Faiferman I; Hirschberg S; Vessey R; Wouters EF Pulm Pharmacol Ther; 2008; 21(2):385-92. PubMed ID: 18023600 [TBL] [Abstract][Full Text] [Related]
6. An oral selective M3 cholinergic receptor antagonist in COPD. Lu S; Parekh DD; Kuznetsova O; Green SA; Tozzi CA; Reiss TF Eur Respir J; 2006 Oct; 28(4):772-80. PubMed ID: 16870658 [TBL] [Abstract][Full Text] [Related]
7. Effect of ipratropium bromide on airway and pulmonary muscarinic receptors in a rat model of chronic obstructive pulmonary disease. Yao W; Wang G; Zhu H; Sun Y; Zhao M Chin Med J (Engl); 2001 Jan; 114(1):80-3. PubMed ID: 11779443 [TBL] [Abstract][Full Text] [Related]
8. Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD. Martin RJ; Bartelson BL; Smith P; Hudgel DW; Lewis D; Pohl G; Koker P; Souhrada JF Chest; 1999 May; 115(5):1338-45. PubMed ID: 10334150 [TBL] [Abstract][Full Text] [Related]
9. Bronchodilator response of advanced lung function parameters depending on COPD severity. Jarenbäck L; Eriksson G; Peterson S; Ankerst J; Bjermer L; Tufvesson E Int J Chron Obstruct Pulmon Dis; 2016; 11():2939-2950. PubMed ID: 27932874 [TBL] [Abstract][Full Text] [Related]
10. A multicenter study of nebulized bronchodilator solutions in chronic obstructive pulmonary disease. Friedman M Am J Med; 1996 Jan; 100(1A):30S-39S. PubMed ID: 8610715 [TBL] [Abstract][Full Text] [Related]
11. Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD. Norris V; Ambery C Pulm Pharmacol Ther; 2013 Oct; 26(5):574-80. PubMed ID: 23524017 [TBL] [Abstract][Full Text] [Related]
12. [Regulation of bronchial tone in chronic obstructive pulmonary disease (COPD): role of muscarinic receptors]. Abad Santos F; Novalbos J; Gallego Sandín S; Gálvez Múgica MA An Med Interna; 2003 Apr; 20(4):201-5. PubMed ID: 12768836 [TBL] [Abstract][Full Text] [Related]
13. Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators. Halpin DM; Kaplan AG; Russell RK Respir Med; 2017 Jul; 128():28-41. PubMed ID: 28610667 [TBL] [Abstract][Full Text] [Related]
14. Double-blind randomized parallel group study comparing the efficacy and safety of tiotropium and ipratropium in the treatment of COPD patients in Taiwan. Hsu JY; Perng RP; Lu JY; Wu CP; Huang MS; Luh KT; Yang PC J Formos Med Assoc; 2006 Sep; 105(9):708-14. PubMed ID: 16959618 [TBL] [Abstract][Full Text] [Related]
15. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease. Colice GL Am J Med; 1996 Jan; 100(1A):11S-18S. PubMed ID: 8610712 [TBL] [Abstract][Full Text] [Related]
16. Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Barnes PJ; Belvisi MG; Mak JC; Haddad EB; O'Connor B Life Sci; 1995; 56(11-12):853-9. PubMed ID: 10188785 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD. Bhattacharya A; Bhargava S; Singh V; Talwar D; Whig J; Rebello J; Purandare S; Gogtay J Int J Chron Obstruct Pulmon Dis; 2016; 11():1469-76. PubMed ID: 27418820 [TBL] [Abstract][Full Text] [Related]
18. Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease. Ikeda A; Nishimura K; Koyama H; Tsukino M; Mishima M; Izumi T Thorax; 1996 Jan; 51(1):48-53. PubMed ID: 8658369 [TBL] [Abstract][Full Text] [Related]
19. The development of anticholinergics in the management of COPD. Scullion JE Int J Chron Obstruct Pulmon Dis; 2007; 2(1):33-40. PubMed ID: 18044064 [TBL] [Abstract][Full Text] [Related]
20. [Lung function and exercise tolerance after treatment with salmeterol or ipratropium bromide in chronic obstructive pulmonary disease]. Grzanka A; Pitsch T; Krzywiecki A; Rogala B Pol Merkur Lekarski; 2004 Sep; 17(99):208-11. PubMed ID: 15628041 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]